关键词
How to Cite
摘要
Золотосодержащие комплексные соединения (ЗСК) проявляют противоопухолевую активность in vivo на моделях ксенографтов опухолей человека и перевиваемых опухолей животных, а также обладают цитотоксическим эффектом in vitro, установленным на широкой панели клеточных линий опухолей человека. ЗСК эффективны в отношении опухолей, резистентных к соединениям платины. Механизмы действия ЗСК и производных цисплатины имеют существенные различия. Основными мишенями для действия ЗСК, в отличие от соединений платины, являются белки, в том числе митохондриальная тиоредоксин-редуктаза и протеасома 26S, ингибирование которых препаратами золота ведет к индукции апоптоза.
参考
Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов, 2014. -Москва, «Практическая медицина». - С. 333.
Островская Л.А., Воронков М.Г., Корман Д.Б. и др. Полиакрилаты благородных металлов, как потенциальные противоопухолевые препараты // Биофизика. - 2014. - Т 59. - вып. 4. - С. 785-789.
Островская Л.А., Грехова А.К., Корман Д.Б. и др. Клеточные эффекты противоопухолевого препарата аурумакрил // Биофизика - 2017. - Т. 62. - вып. 3 - С. 598-603.
Островская Л.А., Корман Д.Б., Грехова А.К. и др. Экспериментальное исследование противоопухолевого эффекта препарата аурумакрил // Известия АН, серия химическая. - 2017. - № 12. - С. 2333-2338.
Платэ Н.А., Васильев А.Е. Физиологически активные полимеры, 1986. - Москва, «Химия». - С. 293.
Радченко Ш., Абзаева К.А., Корман Д.Б. и др. Супертушение флюоресценции интеркалированного в ДНК цианинового красителя при комплексообразовании с полиакрилатом золота // Химия высоких энергий. - 2017. - Т. 52. - № 3. - С. 256-257.
Aldinucci D., Lorenzon I.D., Stefan L. et al. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamato derivatives on human acute myeloid leukemia cells in vitro // Anticancer Drugs. - 2007. - Vol. 8. - P. 323-332.
Altaf M., Monim-ul-Mehboob M., Kawde A.N. et al. New bipiridin gold(III) dithiocarbamato-containing complexes exerted a potent anticancer activity against cisplatin-re-sistant cancer cells independent of p53 status // Onco-target. - 2017. - Vol. 8. - P 490-505.
Cattaruza L., Fregona D., Mongiat M. et al. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts // Int. J. Cancer. - 2011. - Vol. 128. - P. 206-215.
Celegato M., Fregona D., Mongiat M. et al. Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts // Future Med.Chemestry. - 2014. - Vol. 6. - P. 1249 -1263.
Celegato M., Borghese C., Casagrande N. et al. Pre-clinical activity of repurposed drug auranofin in classical Hodgkin lymphoma // Blood. - 2015. - Vol. 126. - P. 1394-1397.
Chen X., Shi X., Wang X., Liu J. Novel use of old drug: anti-reumatic agent auranofin overcomes imatinib-resis-tance of chronic myeloid leukemia cells // Cancer Cell Micrroenviron. - 2014. - № 1. - e415.
Chen X., Shi X.,Zhao C. et al. Anti-reumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl dependent and undependet mechanisms // Oncotarget. - 2014. - Vol. 19. - P. 9118-9132.
Chow H., Sun R.W., Lam J.B. et al. A gold(III) porphyrin complex with antitumor properties targets the Wut/ß-catenin pathway // Cancer Res. - 2010. - Vol. 70. - P.329-337.
Chung C.Y, Fung S.K., Tong K.C. et al. A multi-functional PEGylated gold(III) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery // Chem.Soc. - 2011. - Vol. 8. - P. 1942 -1953.
De Ameida A.M., de Oleveira B.A., de Castro P.P. Lypophilic gold(III) complexes with 1,3,4-oxadiazol-2-thione or 1,3-thriazolidine-2- thione moieties: synthesis and their cytotoxic and antimicribial activities // Biometals. - 2017. - Vol. 30. - P. 841-857.
Fan C. Zheng W., Fu X. et al. Enhancement of aura-nofin-induced lung cancer cell apoptosis by selenocys-tine, a nature inhibitor of TrxRI in vitro and in vivo // Cell Death Dis. - 2014. - № 5. - e. 1191 ( 1038/cddis.2014.32). DOI: 10.1038/cddis.2014.32
Fiscus W., Saba N., Shen M. et al. Auranofin induces lethal oxidative and endoplaplasmic reticulum stress and exerts potent precinical activity against chronic lymphocytic leukemia // Cancer Res. - 2014. - Vol. 74. - P. 2520-2532.
Frezza M., Hindo S., Chen D. et al. Nobel metals and metal complexes as platforms for cancer therapy // Curr. Pharm. Des. - 2010. - Vol. 16. - P. 1813-1825.
Gandin V., Fernandes A.P., Rigobello M.P. Cancer cell death induced by phosphine gold(I) compounds targeting thoredoxin reductase // Biochem. Pharmacol. - 2010. - Vol. 78. - P. 90-101.
He M.F., Gao X.P., Li S.C. et al. Anti-angiogenic effect of auranofin on HEVECs in vitro and zebrafish in vivo // Eur. J. Pharmacol. - 2014. - Vol. 740. - P. 240-247.
Iwasama S., Yamano Y, Takiguchi Y. et al. Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma // Oncol. Rep. - 2011. - Vol. 25. - P. 637644.
Kim I.S., Jin J.Y, lee H., Park S.I. Auranofin induces apoptosis and when combined with retinoic acid enhances dif-ferantion of acute promielocytic leukemia cells in vitro // Br. J. Pharmacol. - 2004. - Vol. 142. - P. 749-755.
Kim N.H., Lee M.Y, Park S.J. Auranofin blocks interleukin-6 signaling by inhibitibg phosphorylation of JAK and STAT3 // Immunology. - 2007. - Vol. 122. - P. 607614.
Kim N.H., Park H.J., Oh M.K., Kim I.S. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activiry in MDA-MB-231 human breast cancer cells // BMB Rep. - 2013. - Vol. 13. - P. 59-64.
Kondom M.N., Ronconi L., Celegato M. et al. Toward selective delivery of chemotherapeutics into tumor cells by targeting peptide treansporters: tailorad gold-based anticancer peptidomimetics //J. Med. Chem. - 2012. - Vol. 55. - P. 2212-2226.
Kostova I. Gold coordination complexes anticancer agents // Anti-cancer Agents in Med. Chem. - 2006. - Vol. 6. - P. 19-32.
Landini I., Lapucci A., Pratesi A. et al. Selection and char-actertization of a human ovarian cancer cell line resistant to auranofin // Oncotarget. - 2017. - Vol. 8. - P. 96062-96078.
Li H., Hu J., Wu S. et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in nonsmall cell lung cancer cells // Oncotarget. - 2016. - Vol. 7. - P. 3548-3558.
Lincoln D.T., Al-Yatama F., Mohammed F.M. et al. Tio-redoxin and thioredoxin reductase expression in thyroid cancer depends on tumor agressivenes // Anticancer Rers. - 2010. -Vol. 30. - P. 767-775.
Liu J.J., Liu Q., Wei H.L. et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells // Pharmazie. - 2011. - Vol. 66. - P. 440-444.
Liu Y, Li Y, Yu S., Zhao G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents // Curr. Drug Targets. - 2012. - Vol. 13. - P. 1432-1444.
Liu C., Liu Z., Li M. et al. Enhancement of auranofininduced apoptosis in MCF-7 human breast cell by selenocystine, a synergistic inhibitor of thioredoxin reductase // Plos. One - 2013. - Vol. 8(1). - e.53945 ( ). DOI: 10.1371/Jornal.pone.0053945
Liu N., Li X., Huang H. et al. Clinically used antireumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth // Oncotarget. - 2014. - Vol. 5. - P. 5433-5471.
Lu J., Holmgren A. The thioredoxin antioxidant system // Free Radical Biol. Med. - 2014. -Vol. 66. - P. 7587.
Lum C.T., Yang Z.F., Li H.Y Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma // Int. J. Cancer. - 2006. - Vol. 118. - P. 1527-1538.
Marcon G., Carotti S., Coornello M. et al. Gold(III) complexes with bypyridil ligands: solution chemestry, cytotoxi-cyty and DNA binding properties // J. Med. Chem. - 2002. - Vol. 45. -P. 1672-1677.
Markowska A., Kospzak B., Jaszczynska-Nowinka K. et al. Nobel metals in oncology // Comtemp. Oncol. (Pozn.). - 2015. - Vol. 19. - P. 271-275.
Marzano C., Gandin V., Fold A. et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cis-platin-resistant human ovarian cancer cells // Free Rad. Biol. Med. - 2007. -Vol. 42. - P. 872-881.
Marzano C., Ronconi L., Chiara F. et al. Gold(III)-dithio-carbamato anticancer agents: activity: toxicology and histopathological studies in rodents // Int. J. Cancer. - 2011. - Vol. 129. - P. 487-496.
Meier S.M., Gerner C., Keppler B.K. et al. Mass spectrometry uncovers molereactivities of coordination and organometallic gold(III) drug candidates in competitive experiments that correlate with their effects // Inorg. Chem. - 2016. - Vol. 255. - P. 424-4259.
Messori L., Orioli P., Tempi C., Marcon G. Interactions of selected gold(III) complexes with calf thymus DNA // Biochem. Biophys. Res. Comm. - 2001. - Vol. 281. - P. 352-360.
Micale N., Schirmeister T., Ettari R. et al. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activites // J. Inorg. Biochem. - 2014. - Vol. 141. - P. 79-82.
Milacic V., Chen D., Ronconi L. et al. A novel anticancer gold(III) didthiocarbamato compound inhibits the activity of a purified 20S proteosoma and 26S proteosoma in human breast cancer cell culteres and xenografts // Cancer Res. - 2006. - Vol. 66. - P. 10478-10486.
Nakaya A., Sagawa M., Muto A. et al. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kB activity // Leuk. Res. - 2011. - Vol. 35. - P. 242-249.
Nardon C., Schmitt S.M., Yang H. et al. Gold(III)-di-thiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia // PloS One. - 2014. - Vol. 9(1). - e844248.
Nardon C., Boscutti G., Fregona D. Beyond platinums: gold complexes as anticancer agents // Anticancer Res. - 2014. - Vol. 34. - P. 487-492.
Nardon C., Chiara F., Brustolin L. et al. Gold(III)-pyrro-lidine dithiocarbamato derivaties as antineoplastic agents // Chemestry open. - 2015. - Vol. 4. - P. 183-191.
Nardon G., Pettenuzza N., Fregona D. Gold complexes for therapeutic purpose: an update patent review (20102015) // Curr. Med. Chem. - 2016. - Vol. 23. - P. 3374-3403.
Nobili S., Mini E., Landini I. et al. Gold compounds as anticancer agents:chemistry, cellular pharmacology and preclinical studies // Med. Res. Rev. - 2010. - Vol. 30. - P. 550-580.
Oomen D., Yiannakis D. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranifin // Mut. Res. - 2015. - Vol. 784-785. - P. 8-15.
Ostrovskaya L.A., Voronkov M.G., Korman D.B. et al. Experimental Study of Antitumor Activity of Polymetalacry-lates against Animal Trasplantable Tumors // J. of Cancer Therapy. - 2010. - Vol. 1. - № 2. - P. 59-65.
Park S.G., Lee J.G., Berek J.S., Hu M.Y Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53 // Int. J. Oncol. - 2014. - Vol. 45. -P. 1691-1698.
Park N., Chun YJ. Auranofin promotes mitochondrial apoptosis by induction annexinA5 expression and translocation in human prostate cancer cell // J. Toxicol. Environ. Health. - 2014. - Vol. 27. - P. 1467-1476.
Pavic A., Glisic B.D., Vojnovic C. et al. Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: a comparative study with auranofin and sunutuniub // J. Inorg. Biochem. - 2017. - Vol. 174. - P. 156-168.
Pessetto Z.Y, Weir S.J., Sethi G. et al. Drug repurposing for gastrointestinal stromal tumor // Mol. Cancer Ther. - 2013. - Vol. 12. - P. 1299-1309.
Rackham O., Nichols S.J., Leedman P.J. et al. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics target to mitochondria // Biochem. Pharmacol. - 2007. - Vol. 74. - P. 992-1002.
Radenkovic F., Holland O., Vanderlelie J.J., Petkins A.V Selective inhibition of endogenous antioxidants with auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation // Biochem. Pharmacol. - 2017. - DOI: 10.1016/j.bcp.2017.09.009
Rigobello M.P., Folda A., Dahi B. et al. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T-cells // Europ. J. Pharm. - 2008. - Vol. 582. - P. 26-34.
Ronconi L., Mazano C., Zanello P. et al. Gold(III) dithiocarbamate derivatives for the treatment of cancer solution chemestry. DNA binding and hemolytic properties // J. Med. Che. - 2006. -Vol. 49. - P. 1648-1657.
Ronconi L., Aldinucci D., Don Q.P. Fregona D. Latest insights into anticancer activity of gold(III) -dithiocarbamato complexes // Anticancer Agents Med.Chem. - 2010. - Vol. 10. - P. 283-292.
Sachweh M.C., Stafford W.E., Drummond C.J.et al. Redox effects and cytotoxic profiles of MJ25 and auranofin toward malignant melanoma cells // Oncotarget. - 2015. - Vol. 6.р - P. 16488-16506.
Saggioro D., Rigobello M.P., Paloschi L. et al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway // Chem.Biol. - 2007. - Vol. 14. - P. 1128-1139.
Sanchez-de-Diego C., Marmol I., Perez R. et al. The anticancer effect related to disturbances in redox balance on Caco-2 cells caused by an alkynyl gold(1) complex // J.Inorg. Biochem. - 2017. - Vol. 166. - P. 108-121.
Sun R.W., Li C.K., Ma D. et al. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure // Chemistry. - 2010. - Vol.16. - P. 3097-3111.
To Y.F., Sun R.W., Chen Y. et al. Gold (III) porphirin complexes is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo // Intern. J. Cancer. - 2009. - Vol. 124. - P. 1971-1979.
Topkas E., Cai N., Cumming A. Auranofin is a potent suppressor of osteosarcoma metastasis // Oncotarget. - 2016. - Vol. 7. - P. 831-844.
Tu S., Sun R.W., Lin C.M. et al. Gold(III)pophyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon Cancer // Cancer. - 2009. - Vol. 114. - P. 4459-44695.
Wang Y, He Q.Y, Sun R.W et al. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug // Eur. J. Pharmacol. - 2007. - Vol. 554. - P. 115-122.
Wang y., Bonzakoura S., de Mey S.et al. Auraofin ra-diosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species // Oncotarget. - 2017. - Vol. 8. - P. 35728 -35742.
You B.R., Park W.H. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion // Oncol. Rep. - 2016. - Vol. 35. - P. 546-551.
Zhang X., Frezza M., Milacic V. et al. Inhibition of tumor proteasome activity by dithocarbamato comlexes via both redox-dependent and undependent process // J. Cell Biochem. - 2010. - Vol. 109. - P. 162-172.
Zhang J., Li X., Han X. et al. Targeting the thioredoxin system for cancer therapy // Trends Pharmacol. Soc. - 2017. - Vol. 38. - P. 794-808.
Zhang B., Zhang J., Peng S.et al. Thioredoxin reductase inhibitors: a patent view // Expert Opin. Ther. Pat. - 2017. - Vol. 27. - P. 547-556.
Zou T., Lum C.T, Lok C.N. et al. Chemical biology of anticancer gold(III) and gold(I) complexes // Chem. Soc. Rev. - 2015. - Vol. 44. - P. 8786-8801.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018